Overall Morningstar Rating™
Advisor Class Shares
★★★★★
Rated against 1228 funds in the Large Growth Category, based on risk-adjusted returns.

AB LARGE CAP GROWTH FUND

Advisor Class: APGYX

MARKET OVERVIEW

Equities, especially growth stocks, enjoyed another remarkable gain in August. The Russell 1000 Growth Index returned 10.32%, extending year-to-date gains to 30.47%. The strength was surprising given that Republicans and Democrats failed to pass additional fiscal stimulus to compensate for the novel coronavirus shutdown, jeopardizing further unemployment support. Several mega-cap technology companies continued to appreciate and drive the indices higher, most notably the Nasdaq 100, which is now up approximately 40% year to date. The AB Large Cap Growth Fund rose in absolute terms but underperformed its benchmark, the Russell 1000 Growth, for the month and the year-to-date period.

The market has embraced the narrative that the restrictions imposed by the response to COVID-19 have accelerated the adoption of digital solutions, encompassing everything from e-commerce for consumers to the cloud for enterprises. The acceleration of the future is certainly evidenced by lower discount rates; assuming lower interest rates for longer periods support discounting future cash flows at ever-lower rates. The resulting higher valuations are becoming evident in pockets of the technology sector. Time will tell if the front-loading of performance is supported by future profits and quiescent inflation. We have maintained our disciplined approach of evaluating each company's future earnings streams and risk/reward prospects inherent in today's valuation rather than chasing the current momentum. The resulting underweight in technology, particularly Apple and Tesla, penalized relative performance in August.

VISA: BENEFITING FROM THE DIGITIZATION OF CASH PAYMENTS

Visa contributed in the month of August, reversing some previous underperformance. While Visa is both enabling and benefiting from the transition to electronic payments, it has been more negatively impacted by headwinds than other fintech players, such as PayPal, due to double-digit declines in verticals, such as travel and more generally, cross-border transactions. While in-person cross-border transactions decreased by approximately 70% in July, card-not-present cross-border transactions rebounded to 20% growth, indicating that headwinds are temporary, not structural. Despite suffering from fewer in-person transactions, Visa is clearly benefiting from accelerated e-commerce adoption, growing 35% in July versus a 20% trend prior to the pandemic. Overall, the resiliency and balance of Visa's network allowed it to return to positive transaction growth in June.

NIKE: FROM BRICK AND MORTAR TO DIRECT TO CONSUMER

Nike shares also contributed, perhaps reflecting confidence in the reopening of key markets like China or the resumption of its crucial vertical—basketball—with the restart of the NBA season. Investors may also be excited about the pent-up demand for athletic gear and the increased appeal of athleisure over more formal attire; demand certainly boosted key vendor Foot Locker's 19% comparable-sales results in the company's second quarter. Analyzing Foot Locker's strength reaffirms our excitement over our direct-to-consumer thesis for Nike. Foot Locker's online sales increased 173% versus instore sales that declined 8% in the quarter. While stronger and differentiated players like Foot Locker will remain partners, Nike recently announced another round of retail-partner terminations as the company favors its own direct-to-consumer channel (DTC). While DTC has less favorable payment terms, Nike captures full price and margin. Also, Nike can incorporate selling insights faster, thus speeding replenishment and future design. Despite the logistical challenges posed by COVID-19, Nike announced plans to open a new regional service center on the West Coast before the upcoming holiday season to forward-deploy digital inventory, leveraging advanced analytics and demand-sensing capabilities. In a period of uncertainty, actions like these underscore Nike's reinvestment opportunity as it embraces digital transformation.

ILLUMINA: LONG-TERM CONVICTION IN GENE SEQUENCING

Illumina's revenue growth has suffered in recent quarters relative to its historical rates, and the genetic-analytics company has detracted from relative performance as a result. Illumina has not yet fully lapped the slowdown in growth related to consumer genomics, as concerns about privacy weighed on customers of services such as

Past performance does not guarantee future results. Morningstar ratings are specific metrics of performance and do not represent absolute performance of any fund. For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a fund's monthly performance, placing more emphasis on downward variations and rewarding consistent performance. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its three-, five- and ten-year (if applicable) Morningstar Rating metrics. The Fund was rated 4, 4 and 5 stars against 1228, 1091 and 810 funds in the category for the three-, five- and ten- year periods, respectively. The Fund's other share classes may have different performance characteristics.

Ancestry.com and 23andMe. More recently, COVID-19 restrictions have hampered nonessential genetic sequencing at academic labs as many have been shut down or operate at reduced capacity. The company's clinical business, including oncology diagnostics, continues to be resilient, which reinforces the long-term thesis that Illumina enables sequencing as a foundational technology with applications in research and clinical applications, including diagnostics. Illumina is the dominant supplier of instruments and reagents to sequence DNA given its advantages in throughput, accuracy and cost, and we continue to expect elasticity in sequencing demand as costs continue to decline. While currently causing some demand headwinds, COVID-19 may eventually represent an opportunity through research applications and disease surveillance applications.

The top five (held) contributors to relative performance in August were Facebook, Nike, Amazon.com, Visa and Alphabet.

The top five (held) detractors from relative performance in August were Xilinx, Electronic Arts, Illumina, Vertex Pharmaceuticals and UnitedHealth Group.

As always, thank you for your continued support.

Frank Caruso, John Fogarty and Vinay Thapar

AB LARGE CAP GROWTH FUND

Advisor Class: APGYX

AUG 8.31.20

PORTFOLIO INFORMATION

Class	Ticker	Inception Date
A	APGAX	9/28/92
C	APGCX	5/3/93
Advisor	APGYX	10/1/96
I	ALLIX	3/1/05
Z	APGZX	6/30/15

Portfolio Characteristics	Portfolio	Benchmark[1]
Total Number of Holdings	55	434
P/E Ratio (Stock Price/Earnings; last 12 mo)	40.93x	44.65x
P/CF Ratio (Stock Price/Cash Flow)	28.29x	26.67x
ROE (Return on Equity; next 12 mo)	30.90%	37.61%
Median Market Cap ($ Billions)	42.3	14.1
Weighted Market Cap ($ Billions)	406.8	511.0
EPS (Earnings per Share) Growth Rate (2020/2019)	8.34%	3.05%

Portfolio Statistics	
Beta (3 yr)[2]	0.83
Sharpe Ratio (3 yr)[3]	1.36
Standard Deviation (3 yr)[4]	15.72
Alpha (3 yr)[5]	2.22

Top Ten Equity Holdings[6]		
Company	**Sector**	
Microsoft	Information Technology	7.34%
Alphabet	Communication Services	7.17
Facebook	Communication Services	5.38
Amazon.com	Consumer Discretionary	5.25
Visa	Information Technology	4.67
UnitedHealth	Healthcare	4.43
Monster Beverage	Consumer Staples	3.83
Zoetis	Healthcare	3.40
Vertex Pharmaceuticals	Healthcare	3.28
Intuitive Surgical	Healthcare	3.21

Sector Breakdown[6]	Portfolio	Benchmark[1]
Information Technology	28.51%	44.96%
Healthcare	24.28	13.47
Communication Services	15.11	11.31
Consumer Discretionary	12.60	16.70
Consumer Staples	5.40	4.57
Industrials	4.04	4.44
Materials	1.69	0.78
Financials	0.36	1.91
Cash and Cash Equivalents	8.01	–
Real Estate	–	1.78
Energy	–	0.07
Utilities	–	0.02

Top Five Contributors	Top Five Detractors
Facebook	Xilinx
Nike	Electronic Arts
Amazon.com	Illumina
Visa	Vertex Pharmaceuticals
Alphabet	UnitedHealth Group

1 Russell 1000 Growth Index.
2 Beta measures a fund's volatility relative to its benchmark.
3 Sharpe Ratio is a measure of the fund's return relative to the investment risk it has taken. A higher Sharpe Ratio means the fund's returns have been better given the level of risk the fund has taken.
4 Standard Deviation is a measure of the dispersion of a portfolio's return from its mean.
5 Alpha is the risk-adjusted measurement of 'excess return' over the benchmark.
6 Holdings are expressed as a percentage of total investments and may vary over time. They are provided for informational purposes only and should not be deemed as a recommendation to buy or sell the securities mentioned.

MONTHLY AVERAGE ANNUAL TOTAL RETURNS AS OF 8/31/20: ADVISOR CLASS PERFORMANCE

	1 Mo	YTD	1 Yr	3 Yrs	5 Yrs	10 Yrs	Since Inception
Large Cap Growth Portfolio†^	6.15%	25.33%	38.21%	22.98%	19.83%	19.51%	10.34%
Russell 1000 Growth Index	10.32	30.47	44.34	24.18	20.66	19.02	9.70
Morningstar Large Growth Category	8.37	25.20	36.21	20.26	17.12	16.65	8.61

QUARTERLY AVERAGE ANNUAL TOTAL RETURNS AS OF 6/30/20: ADVISOR CLASS PERFORMANCE

	QTD	YTD	1 Yr	3 Yrs	5 Yrs	10 Yrs	Since Inception	Expense Ratios as of 10/31/19	
Large Cap Growth Portfolio†^	25.40%	11.23%	23.44%	19.77%	16.31%	18.08%	9.86%	Gross	0.65%
Russell 1000 Growth Index	27.84	9.81	23.28	18.99	15.89	17.23	8.98	Net‡	0.64%
Morningstar Large Growth Category	27.43	7.84	17.34	15.95	12.84	15.12	8.01		

The performance shown above represents past performance and does not guarantee future results. Current performance may be lower or higher than the performance information shown. You may obtain performance information current to the most recent month-end by visiting www.abfunds.com. The investment return and principal value of an investment in the Portfolio will fluctuate, so that your shares, when redeemed, may be worth more or less than their original cost. Advisor Class shares have no front-end or contingent deferred sales charges, however when purchased through a financial advisor additional fees may apply. Returns for other share classes will vary due to different charges and expenses. Performance assumes reinvestment of distributions and does not account for taxes. If applicable, high double-digit returns are highly unusual and cannot be sustained; such returns are primarily achieved during favorable market conditions.

† The Fund's Advisor Class share inception date is 10/1/96 and is the date used to calculate since inception annualized performance.

^ Reflects a 2.77% and 15.92% increase in NAV on January 18, 2011 and December 23, 2008, respectively, from the proceeds of the Enron class action settlement. Reflects a 0.38% and 0.08% increase in NAV on June 8, 2016 and November 2, 2017 as a result of the Fund recording a receivable on its books and records in connection with the distributions by the Alliance Fair Fund and Bank of America Fair Fund, respectively.

‡ If applicable, this reflects the Adviser's contractual waiver of a portion of its advisory fee and/or reimbursement of a portion of the Fund's operating expenses. Absent reimbursements or waivers, performance would have been lower.

Russell 1000 Growth Index represents the performance of large-cap growth companies within the US.

Investors cannot invest directly in indices or averages, and their performance does not reflect fees and expenses or represent the performance of any AB fund.

Sources: FactSet, Morningstar Inc. and AB.

A WORD ABOUT RISK

Market Risk: The market values of the portfolio's holdings rise and fall from day to day, so investments may lose value. **Focused Portfolio Risk:** Portfolios that hold a smaller number of securities may be more volatile than more diversified portfolios, since gains or losses from each security will have a greater impact on the portfolio's overall value. **Foreign (Non-US) Risk:** Non-US securities may be more volatile because of political, regulatory, market and economic uncertainties associated with such securities. Fluctuations in currency exchange rates may negatively affect the value of the investment or reduce returns. These risks are magnified in emerging or developing markets. **Derivatives Risk:** Investing in derivative instruments such as options, futures, forwards or swaps can be riskier than traditional investments, and may be more volatile, especially in a down market.

UMF-139171-2020-09-04
LCG-11EC-0820